This site is not optimized for mobile devices. For the best mobile experience we suggest you download our mobile app!
Download on App Store App Store Icon App Store Google Play Store Icon Google Play

ARV Dosing: Hepatic Impairment

Dose Adjustment of ARVs for Impaired Hepatic Function

NRTIs

ARV Dose Adjustment
ABC Child-Pugh Class A: 200 mg bid (use oral solution)
Child-Pugh Class B or C: contraindicated
FTC No dosage adjustment
3TC No dosage adjustment
TAF No dosage adjustment
TAF/FTC No dosage adjustment
TDF No dosage adjustment
TDF/FTC No dosage adjustment
ZDV Reduce dose by 50% or double the interval between doses if Child-Pugh Class C

NNRTIs

ARV Dose Adjustment
EFV No dosage adjustment; use with caution in persons with hepatic impairment
TDF/FTC/EFV No dosage adjustment; use with caution in persons with hepatic impairment
ETV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
NVP Child-Pugh Class B or C: contraindicated
RPV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
TAF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
TDF/FTC/RPV Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
TDF/3TC/DOR Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data
DOR Child-Pugh Class A or B: no dosage adjustment
Child Pugh Class C: no data

PIs

ARV Dose Adjustment
ATV Child-Pugh Class A: no dose adjustment
Child-Pugh Class B: 300 mg qd (unboosted)
Child-Pugh Class C: not recommended
ATV/c Child-Pugh Class A: use with caution
Child-Pugh Class B or C: not recommended
COBI Refer to recommendations for the primary PI
DRV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
TAF/FTC/DRV/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended
LPV/r

Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: not recommended

RTV Refer to recommendations for the primary PI

AI

ARV Dose Adjustment
FTR No dosage adjustment

FI

ARV Dose Adjustment
ENF No dosage adjustment

EI

ARV Dose Adjustment
Ibalizumab No dosage adjustment

CCR5 Inhibitor

ARV Dose Adjustment
MVC No dosage recommendations. Concentrations will likely be increased in persons with hepatic impairment

Capsid Inhibitor

ARV Dose Adjustment
LEN Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, use with caution

INSTI

Agent Dose Adjustment
RAL Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, use with caution
EVG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
DTG Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, use with caution
DTG/3TC Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, use with caution
DTG/RPV Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
BIC Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
TAF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
TDF/FTC/EVG/c Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
ABC/3TC/DTG Use separate compounds and refer to those adjustments
TAF/FTC/BIC Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data, not recommended
CAB Child-Pugh Class A or B: no dosage adjustment
Child-Pugh Class C: no data
Note: Hepatic dysfunction is a good indication for TDM as clinical experience with these dose adjustments is very limited